天宇股份替米沙坦工艺II原料药获得CEP证书

Group 1 - The core point of the article is that Tianyu Co., Ltd. has received the CEP certificate from the European Medicines Agency for the active pharmaceutical ingredient of Telmisartan, which is used for treating primary hypertension and reducing cardiovascular risk [1] Group 2 - The announcement highlights the significance of the CEP certificate in ensuring the quality and compliance of the pharmaceutical product in the European market [1] - Telmisartan is specifically indicated for the treatment of primary hypertension and plays a role in lowering cardiovascular risk, indicating its importance in the healthcare sector [1]